CDK9 and colorectal cancer: Moreover, CDK9 inhibition by Dinaciclib resulted in markedly decreased colorectal cancer cell viability and profoundly enhanced TRAIL-mediated apoptosis of resistant colorectal cancer cells via suppression of short-living anti-apoptotic proteins Mcl-1 and c-FLIP.